Publicaciones en colaboración con investigadores/as de University of Chicago Medical Center (4)

2022

  1. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Nature Medicine, Vol. 28, Núm. 2, pp. 325-332

2020

  1. First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317

2019

  1. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 5, pp. 421-431

2010

  1. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

    Blood, Vol. 116, Núm. 25, pp. 5650-5659